{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:32Z","timestamp":1793212112969,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012623","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000}}],"reference-count":113,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012623.pub2","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T17:09:29Z","timestamp":1700500169000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Infliximab for medical induction of remission in Crohn's disease"],"prefix":"10.1002","volume":"2023","author":[{"given":"Morris","family":"Gordon","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Sinopoulou","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony K","family":"Akobeng","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology; Sidra Medicine; Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shellie J","family":"Radford","sequence":"additional","affiliation":[{"name":"NIHR Nottingham Biomedical Research Centre \u2013 Gastrointestinal and Liver disorders theme; Nottingham University Hospitals NHS Trust; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Eldragini","sequence":"additional","affiliation":[{"name":"NIHR Nottingham Biomedical Research Centre \u2013 Gastrointestinal and Liver disorders theme; Nottingham University Hospitals NHS Trust; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Darie","sequence":"additional","affiliation":[{"name":"NIHR Nottingham Biomedical Research Centre \u2013 Gastrointestinal and Liver disorders theme; Nottingham University Hospitals NHS Trust; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon William","family":"Moran","sequence":"additional","affiliation":[{"name":"National Institute of Health Research Nottingham Biomedical Research Centre; University of Nottingham and Nottingham University Hospitals; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD012623.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13139","article-title":"Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease \u2013 a SONIC post hoc analysis","volume":"41","author":"Colombel","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD012623.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1873-9946(09)60114-8","article-title":"SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy","volume":"3","author":"Colombel","year":"2009","journal-title":"Journal of Crohn's and Colitis"},{"issue":"15","key":"10.1002\/14651858.CD012623.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012623.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1873-9946(13)60017-3","article-title":"Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial","volume":"7","author":"Peyrin-Biroulet","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1873-9946(13)60017-3","article-title":"Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial","volume":"7","author":"Peyrin-Biroulet","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0007|cit7","first-page":"s13","article-title":"SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy","volume":"15","author":"Sandborn","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"751f","DOI":"10.1016\/S0016-5085(09)60521-7","article-title":"One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy","volume":"136","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012623.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial","volume":"116","author":"D'Haens","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0011|cit11","first-page":"110","article-title":"A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease","volume":"130","author":"D'Haens","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012623.pub2-BIB0012|cit12","first-page":"229","article-title":"Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease","volume":"18","author":"Duan","year":"2013","journal-title":"Chinese Journal of Gastroenterology"},{"issue":"9317","key":"10.1002\/14651858.CD012623.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012623.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1002\/14651858.CD012623.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.14309\/ajg.0000000000001111","article-title":"Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: an ACCENT-II post hoc analysis","volume":"116","author":"Papamichael","year":"2021","journal-title":"American Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD012623.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1002\/14651858.CD012623.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0019|cit19","first-page":"1139","article-title":"Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results","volume":"5","author":"Kim","year":"2017","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/ecco-jcc\/jjx002.098","article-title":"Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results","volume":"11","author":"Kim","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0016-5085(17)30571-1","article-title":"Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (INX) in patients with active Crohn's disease: early efficacy and safety results","volume":"152","author":"Kim","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(18)30972-7","article-title":"Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results","volume":"154","author":"Ye","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0023|cit23","first-page":"385","article-title":"Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn's disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial","volume":"8","author":"Ye","year":"2020","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","article-title":"Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study","volume":"393","author":"Ye","year":"2019","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1097\/01.MIB.0000480181.61935.67","article-title":"Randomized clinical trial for clinical response evaluation in Crohn's disease: infliximab versus adalimumab","volume":"22","author":"Baima","year":"2016","journal-title":"Inflammatory Bowel Diseases"},{"issue":"1","key":"10.1002\/14651858.CD012623.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00054725-200201000-00012","article-title":"Infliximab as first-line therapy for severe Crohn's disease?","volume":"8","author":"Bernstein","year":"2002","journal-title":"Inflammatory Bowel Diseases"},{"issue":"10","key":"10.1002\/14651858.CD012623.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjaa050","article-title":"Combined biologic and immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease-related complications","volume":"14","author":"Bernstein","year":"2020","journal-title":"Journal of Crohn's and Colitis"},{"issue":"7","key":"10.1002\/14651858.CD012623.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/apt.13754","article-title":"Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience","volume":"44","author":"Billiet","year":"2016","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD012623.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/apt.16478","article-title":"Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study","volume":"54","author":"Blesl","year":"2021","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD012623.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00042737-200601000-00003","article-title":"Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study","volume":"18","author":"Blumenstein","year":"2006","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD012623.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.dld.2017.11.008","article-title":"Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease","volume":"50","author":"Bodini","year":"2018","journal-title":"Digestive and Liver Disease"},{"issue":"9","key":"10.1002\/14651858.CD012623.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.crohns.2012.10.019","article-title":"Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease","volume":"7","author":"Bortlik","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1093\/ecco-jcc\/jjy222.389","article-title":"Pharmacokinetic and pharmacodynamic evaluation of radiological healing in Crohn's disease patients treated with infliximab: a TAILORIX MRE substudy","volume":"13","author":"Bossuyt","year":"2019","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0034|cit34","first-page":"32","article-title":"Ultraproactive therapeutic drug monitoring based on point-of-care testing of infliximab is not superior to reactive drug monitoring in patients with inflammatory bowel disease: 1 year results of a pragmatic clinical trial","volume":"8(8 Suppl)","author":"Bossuyt","year":"2020","journal-title":"United European Gastroenterology Journal"},{"issue":"8","key":"10.1002\/14651858.CD012623.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1080\/00365521.2020.1786852","article-title":"Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease","volume":"55","author":"Buhl","year":"2020","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/MEG.0000000000001706","article-title":"Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease","volume":"32","author":"Chaparro","year":"2020","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","article-title":"Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis","volume":"17","author":"Colombel","year":"2019","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/S0016-5085(16)30583-2","article-title":"Drug-level based dosing versus symptom-based dose adaptation in patients with Crohn's disease: a prospective, randomized multicenter study (TAILORIX)","volume":"1","author":"D'Haens","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0039|cit39","unstructured":"Multicenter comparative study between nutritional therapy alone and anti-TNF-alpha monoclonal antibody in inducing and maintaining remission in pediatric Crohn's disease: a randomized controlled trial \u2013 nutrition and biologics in Crohn's disease trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2008-006484-36-IT"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0040|cit40","unstructured":"A multicenter trial comparing REMICADE (infliximab) and placebo in the prevention of recurrence in Crohn's disease patients undergoing surgical resection who are at an increased risk of recurrence trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2010-018431-18-DE"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0041|cit41","unstructured":"A randomized controlled trial investigating tailored treatment with infliximab for active luminal Crohn's disease trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2011-003038-14-NL"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0042|cit42","unstructured":"Scientific medical research comparing the effectiveness of Infliximab by injection in the abdominal tissue (subcutaneous) monotherapy and infliximab subcutaneous injection with anti-inflammatory drugs in the treatment of moderate to severe chronic inflammatory bowel disease trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2021-000469-33-NL"},{"issue":"3","key":"10.1002\/14651858.CD012623.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0044|cit44","unstructured":"Fu M Liu H Chenv S Preliminary study on treatment of Crohn's disease with infliximab Unknown 2011 26 8"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"e038429","DOI":"10.1136\/bmjopen-2020-038429","article-title":"Laparoscopic bowel resection combined with infliximab treatment (LaRIC) versus infliximab for terminal ileitis in Crohn's disease: a randomised, controlled, open-label trial","volume":"10","author":"Hao","year":"2020","journal-title":"BMJ Open"},{"issue":"8","key":"10.1002\/14651858.CD012623.pub2-BIB0046|cit46","first-page":"1140","article-title":"Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative subgroup analyses in Crohn's disease and ulcerative colitis in the nor-switch extension trial","volume":"5","author":"Jorgensen","year":"2019","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012623.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00054725-200207000-00001","article-title":"Infliximab improves quality of life in patients with Crohn's disease","volume":"8","author":"Lichtenstein","year":"2002","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0049|cit49","first-page":"379","article-title":"Predictors of response to infliximab in patients with fistulizing Crohn's disease","volume":"96","author":"Luna-Chadid","year":"2003","journal-title":"Revista Espanola De Enfermedades Digestivas"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0050|cit50","first-page":"A54","article-title":"A prospective, randomized trial of infliximab (IFX) and azathioprine (AZA) for the induction and maintenance of remission of steroid-dependent Crohn's disease (CD)","volume":"126","author":"Mantzaris","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0051|cit51","unstructured":"Mantzaris GJ Polyzou P Karagiannidis A Christidou A Koilakou S Tsounis D A prospective, randomized trial of infliximab (IFX) and azathioprine (AZA) for the induction and maintenance of remission of steroid-dependent Crohn's disease Digestive Disease Week conference; 2004 May 15-20; New Orleans (LA) 2004"},{"issue":"7","key":"10.1002\/14651858.CD012623.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00008571-200210000-00002","article-title":"Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials","volume":"12","author":"Mascheretti","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0053|cit53","first-page":"s1542","article-title":"Comparative efficacy and rapidity of action for infliximab vs ustekinumab in biologic naive Crohn's disease","volume":"21","author":"Narula","year":"2021","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0054|cit54","unstructured":"Phase III randomized study of anti-tumor necrosis factor chimeric monoclonal antibody (cA2) for patients with enterocutaneous fistulae as a complication of Crohn's disease clinicaltrials.gov\/study\/NCT00004941"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0055|cit55","unstructured":"Study investigating tailored treatment with infliximab for active Crohn's disease clinicaltrials.gov\/study\/NCT01442025"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0056|cit56","unstructured":"A phase I study to evaluate pharmacokinetics, efficacy and safety of CT-P13 subcutaneous in patients with active Crohn's disease and ulcerative colitis clinicaltrials.gov\/study\/NCT02883452"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0057|cit57","unstructured":"The OPTIMIZE trial clinicaltrials.gov\/show\/NCT04835506"},{"issue":"4","key":"10.1002\/14651858.CD012623.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"e057656","DOI":"10.1136\/bmjopen-2021-057656","article-title":"Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)","volume":"12","author":"Papamichael","year":"2022","journal-title":"BMJ Open"},{"issue":"3","key":"10.1002\/14651858.CD012623.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ibd.20788","article-title":"Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on-demand maintenance therapy","volume":"15","author":"Ruemmele","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4","key":"10.1002\/14651858.CD012623.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD012623.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease","volume":"63","author":"Rutgeerts","year":"2005","journal-title":"Gastrointestinal Endoscopy"},{"issue":"3","key":"10.1002\/14651858.CD012623.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1155\/2002\/379307","article-title":"Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta","volume":"16","author":"Sample","year":"2002","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD012623.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/bcp.14229","article-title":"A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease","volume":"86","author":"Sanchez-Hernandez","year":"2020","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD012623.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"Schroder O Blumenstein I Stein J Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study European Journal of Gastroenterology & Hepatology 2006 18 1 11 6","DOI":"10.1097\/00042737-200601000-00003"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Sorrentino D Paviotti A Zarifi D Geraci M Avellini C Zoli G Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab \u2013 a pilot study Digestive Diseases and Sciences 2012 57 5 1341 8","DOI":"10.1007\/s10620-011-2025-z"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD012623.pub2-BIB0067|cit67","first-page":"abstract 2029","article-title":"Therapeutic drug monitoring compared to standard treatment of patients starting infliximab: results from a multicenter randomized controlled trial of 400 patients","volume":"72","author":"Syversen","year":"2020","journal-title":"American College of Rheumatology"},{"issue":"13","key":"10.1002\/14651858.CD012623.pub2-BIB0068|cit68","first-page":"3734","article-title":"Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)","volume":"21","author":"Syversen","year":"2020","journal-title":"Trials"},{"issue":"17","key":"10.1002\/14651858.CD012623.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial","volume":"325","author":"Syversen","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD012623.pub2-BIB0070|cit70","first-page":"176","article-title":"The impact of induction therapy with three doses of infliximab on deep histological healing in paediatric patients with active Crohn's disease","volume":"11","author":"Szymanska","year":"2016","journal-title":"Przegl\u0105d Gastroenterologiczny"},{"issue":"8","key":"10.1002\/14651858.CD012623.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"e0201956","DOI":"10.1371\/journal.pone.0201956","article-title":"Infliximab for pediatric patients with Crohn's disease: phase 3, open-label, uncontrolled, multicenter trial in Japan","volume":"13","author":"Tajiri","year":"2018","journal-title":"PLOS One"},{"issue":"10","key":"10.1002\/14651858.CD012623.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/ibd.20915","article-title":"Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study","volume":"15","author":"Yamamoto","year":"2009","journal-title":"Inflammatory Bowel Disease"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.3748\/wjg.v21.i8.2475","article-title":"Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease","volume":"21","author":"Yang","year":"2015","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0074|cit74","unstructured":"Efficacy and safety of formulation switching between infliximab SC and IV in patients with Crohn's disease (CHAMELEON Study) trialsearch.who.int\/Trial2.aspx?TrialID=KCT0007470"},{"issue":"4","key":"10.1002\/14651858.CD012623.pub2-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003574.pub2","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease","author":"Akobeng","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012623.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0016-5085(99)70224-6","article-title":"Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis","volume":"116","author":"Baert","year":"1999","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD012623.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2009.09.056","article-title":"Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease","volume":"138","author":"Baert","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0079|cit79","first-page":"129","article-title":"Anti-TNF-alpha antibody treatment for Crohn's disease","volume":"22","author":"Bell","year":"2000","journal-title":"Research and Clinical Forums"},{"issue":"5","key":"10.1002\/14651858.CD012623.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/2050640615590302","article-title":"Biologics in inflammatory bowel disease: what are the data?","volume":"3","author":"Cote-Daigneault","year":"2015","journal-title":"United European Gastroenterology Journal"},{"issue":"5","key":"10.1002\/14651858.CD012623.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial","volume":"116","author":"D'Haens","year":"1999","journal-title":"Gastroenterology"},{"issue":"7109","key":"10.1002\/14651858.CD012623.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD012623.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Harmsen","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD012623.pub2-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010233.pub3","article-title":"Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease","author":"Gjuladin-Hellon","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012623.pub2-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008414.pub3","article-title":"Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease","author":"Gjuladin-Hellon","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/flgastro-2020-101405","article-title":"Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn's disease: a systematic review","volume":"12","author":"Gordon","year":"2021","journal-title":"Frontline Gastroenterology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"7572","DOI":"10.3748\/wjg.v27.i43.7572","article-title":"Minimum sample size estimates for trials in inflammatory bowel disease: a systematic review of a support resource","volume":"27","author":"Gordon","year":"2021","journal-title":"World Journal of Gastroenterology"},{"issue":"7650","key":"10.1002\/14651858.CD012623.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD012623.pub2-BIB0090|cit90","first-page":"793","article-title":"Vedolizumab as a treatment for Crohn's disease and ulcerative colitis","volume":"10","author":"Ha","year":"2014","journal-title":"Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0091|cit91","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0092|cit92","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"9","key":"10.1002\/14651858.CD012623.pub2-BIB0093|cit93","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013210.pub2","article-title":"Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis","author":"Iheozor-Ejiofor","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/2050640620967899","article-title":"Sample-size estimation is not reported in 24% of randomised controlled trials of inflammatory bowel disease: a systematic review","volume":"9","author":"Iheozor-Ejiofor","year":"2021","journal-title":"UEG Journal"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1136\/gutjnl-2019-318936","article-title":"IBD prevalence in Lothian, Scotland, derived by capture\u2013recapture methodology","volume":"68","author":"Jones","year":"2019","journal-title":"Gut"},{"issue":"16","key":"10.1002\/14651858.CD012623.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and initial characterisation of a mouse-human anti-TNF antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Molecular Immunology"},{"issue":"3","key":"10.1002\/14651858.CD012623.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"issue":"9","key":"10.1002\/14651858.CD012623.pub2-BIB0098|cit98","first-page":"1","article-title":"The current and future use of anti-TNF alpha agents in Crohn's disease: is there an unmet need?","volume":"2","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology & Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012623.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences","volume":"126","year":"2004","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD012623.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3109\/00365529509096316","article-title":"Disease activity courses in a regional cohort of Crohn's disease patients","volume":"30","author":"Munkholm","year":"1995","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012623.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2012","journal-title":"Nature Reviews Immunology"},{"issue":"6","key":"10.1002\/14651858.CD012623.pub2-BIB0102|cit102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013747.pub2","article-title":"Certolizumab pegol for maintenance of medically induced remission in Crohn's disease","author":"Okabayashi","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012623.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cgh.2016.06.025","article-title":"Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease","volume":"15","author":"Peyrin-Biroulet","year":"2017","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD012623.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.4049\/jimmunol.159.12.6276","article-title":"A role for TNF alpha mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease","volume":"159","author":"Plevy","year":"1997","journal-title":"Journal of Immunology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JIR.S165330","article-title":"Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives","volume":"11","author":"Rawla","year":"2018","journal-title":"Journal of inflammation research"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0106|cit106","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2020"},{"issue":"4","key":"10.1002\/14651858.CD012623.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s002689900401","article-title":"Cytokines in inflammatory bowel disease","volume":"22","author":"Rogler","year":"1998","journal-title":"World Journal of Surgery"},{"issue":"9","key":"10.1002\/14651858.CD012623.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012623.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0016-5085(94)90614-9","article-title":"Cytokines in intestinal inflammation: patho-physiological and clinical considerations","volume":"106","author":"Sartor","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0110|cit110","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"Journal of Crohn's and colitis"},{"issue":"6","key":"10.1002\/14651858.CD012623.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/j.1572-0241.2006.00552.x","article-title":"Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003\u20132005: a population-based study from the Danish Crohn colitis database","volume":"101","author":"Vind","year":"2006","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012623.pub2-BIB0113|cit113","doi-asserted-by":"crossref","unstructured":"Deol N Nguyen TM Parker CE Khanna R Feagan BG MacDonald JK Infliximab for induction of remission in Crohn's disease Cochrane Database of Systematic Reviews 2017 4 10.1002\/14651858.CD012623","DOI":"10.1002\/14651858.CD012623"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T03:33:33Z","timestamp":1737516813000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012623.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gut Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":113,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012623.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]}}}